Symbols / IMRX $5.45 +2.25% Immuneering Corporation

Healthcare • Biotechnology • United States • NGM
IMRX Chart
About

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 352.36M
Enterprise Value 183.35M Income -56.02M Sales —
Book/sh 3.38 Cash/sh 2.67 Dividend Yield —
Payout 0.00% Employees 53 IPO —
P/E — Forward P/E -4.03 PEG —
P/S — P/B 1.61 P/C —
EV/EBITDA -3.11 EV/Sales — Quick Ratio 17.16
Current Ratio 17.50 Debt/Eq 1.75 LT Debt/Eq —
EPS (ttm) -1.27 EPS next Y -1.35 EPS Growth —
Revenue Growth — Earnings 2026-05-05 ROA -26.07%
ROE -43.12% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 64.65M
Shs Float 49.40M Short Float 20.05% Short Ratio 15.29
Short Interest — 52W High 10.08 52W Low 1.10
Beta 0.43 Avg Volume 1.62M Volume 597.45K
Target Price $17.00 Recom None Prev Close $5.33
Price $5.45 Change 2.25%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.00
Mean price target
2. Current target
$5.52
Latest analyst target
3. DCF / Fair value
$-7.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.52
Low
$11.00
High
$30.00
Mean
$17.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-09 reit Needham Buy → Buy $11
2025-11-13 main Chardan Capital Buy → Buy $20
2025-10-31 init Leerink Partners — → Outperform $15
2025-09-30 reit HC Wainwright & Co. Buy → Buy $11
2025-09-26 main Chardan Capital Buy → Buy $20
2025-09-25 main Oppenheimer Outperform → Outperform $30
2025-09-15 main Needham Buy → Buy $11
2025-08-26 reit Needham Buy → Buy $8
2025-08-14 main Chardan Capital Buy → Buy $13
2025-06-18 main Mizuho Outperform → Outperform $10
2025-06-18 reit Needham Buy → Buy $9
2025-06-18 main Chardan Capital Buy → Buy $13
2025-06-05 reit Needham Buy → Buy $9
2025-05-07 main Oppenheimer Outperform → Outperform $21
2025-05-06 main Chardan Capital Buy → Buy $13
2025-04-10 reit Needham Buy → Buy $12
2025-03-24 main Chardan Capital Buy → Buy $13
2025-03-21 reit Needham Buy → Buy $12
2025-02-06 reit Needham Buy → Buy $12
2025-01-13 reit Needham Buy → Buy $15
News
RSS: Latest IMRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 NEUFELD LEAH R Officer — 3,628 $4.29 $15,573
2026-01-16 BRAKEWOOD HAROLD EUGENE Officer — 5,250 $4.76 $24,990
2026-01-15 HALL BRETT MATTHEW Officer — 2,298 $4.57 $10,502
2026-01-15 SCHALL THOMAS J Director — 21,645 $4.67 $101,041
2026-01-13 NEUFELD LEAH R Officer — 2,626 $4.15 $10,906
2026-01-12 FEINBERG PETER Director — 20,000 $4.35 $86,904
2025-10-03 FEINBERG PETER Director — 7,500 $6.67 $50,025
2025-10-01 MORALES MALLORY Officer — 300 $6.39 $1,917
2025-10-01 NEUFELD LEAH R Officer — 800 $6.38 $5,103
2025-10-01 BOOKMAN MICHAEL Officer — 1,020 $6.83 $6,966
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.32
Operating Revenue
0.00
0.00
0.00
-100.00%
0.32
Cost Of Revenue
—
—
0.00
-100.00%
0.16
Reconciled Cost Of Revenue
—
—
0.00
-100.00%
0.16
Gross Profit
—
—
0.00
-100.00%
0.16
Operating Expense
59.38
-7.33%
64.07
+9.69%
58.41
+12.54%
51.90
Research And Development
42.05
-12.33%
47.96
+15.23%
41.62
+14.77%
36.27
Selling General And Administration
17.30
+7.59%
16.08
-4.07%
16.76
+7.39%
15.61
General And Administrative Expense
17.30
+7.59%
16.08
-4.07%
16.76
+7.39%
15.61
Salaries And Wages
12.44
+3.63%
12.00
+1.17%
11.86
+16.27%
10.20
Other Gand A
4.86
+19.22%
4.08
-16.76%
4.90
-9.38%
5.41
Total Expenses
59.38
-7.33%
64.07
+9.69%
58.41
+12.20%
52.06
Operating Income
-59.38
+7.33%
-64.07
-9.69%
-58.41
-12.89%
-51.75
Total Operating Income As Reported
-59.38
+7.33%
-64.07
-9.69%
-58.41
-12.89%
-51.74
EBITDA
-59.02
+7.32%
-63.69
-9.69%
-58.06
-12.81%
-51.47
Normalized EBITDA
-59.02
+7.32%
-63.69
-9.69%
-58.06
-12.81%
-51.47
Reconciled Depreciation
0.35
-8.13%
0.39
+9.37%
0.35
+26.99%
0.28
EBIT
-59.38
+7.33%
-64.07
-9.69%
-58.41
-12.89%
-51.75
Net Income
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Pretax Income
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Net Non Operating Interest Income Expense
3.04
+17.20%
2.59
-28.10%
3.61
+255.56%
1.01
Net Interest Income
3.04
+17.20%
2.59
-28.10%
3.61
+255.56%
1.01
Interest Income Non Operating
3.04
+17.20%
2.59
-28.10%
3.61
+255.56%
1.01
Interest Income
3.04
+17.20%
2.59
-28.10%
3.61
+255.56%
1.01
Other Income Expense
0.31
-29.41%
0.44
-66.91%
1.33
+515.31%
0.22
Other Non Operating Income Expenses
0.31
-29.41%
0.44
-66.91%
1.33
+515.31%
0.22
Tax Provision
—
—
—
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Net Income From Continuing Operation Net Minority Interest
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Net Income From Continuing And Discontinued Operation
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Net Income Continuous Operations
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Normalized Income
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Net Income Common Stockholders
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Diluted EPS
—
-2.04
-8.51%
-1.88
+1.57%
-1.91
Basic EPS
—
-2.04
-8.51%
-1.88
+1.57%
-1.91
Basic Average Shares
—
29.98
+5.51%
28.42
+7.69%
26.39
Diluted Average Shares
—
29.98
+5.51%
28.42
+7.69%
26.39
Diluted NI Availto Com Stockholders
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Amortization
0.03
+0.00%
0.03
+0.00%
0.03
-2.62%
0.03
Amortization Of Intangibles Income Statement
0.03
+0.00%
0.03
+0.00%
0.03
-2.62%
0.03
Depreciation Amortization Depletion Income Statement
0.03
+0.00%
0.03
+0.00%
0.03
-2.62%
0.03
Depreciation And Amortization In Income Statement
0.03
+0.00%
0.03
+0.00%
0.03
-2.62%
0.03
Rent And Landing Fees
—
—
—
—
Rent Expense Supplemental
—
—
—
—
Line Item Trend 2023-12-31
Total Assets
102.58
Current Assets
89.08
Cash Cash Equivalents And Short Term Investments
85.67
Cash And Cash Equivalents
59.41
Other Short Term Investments
26.26
Receivables
0.00
Accounts Receivable
0.00
Prepaid Assets
—
Other Current Assets
3.42
Total Non Current Assets
13.50
Net PPE
5.40
Gross PPE
6.12
Accumulated Depreciation
-0.73
Properties
0.00
Machinery Furniture Equipment
0.65
Construction In Progress
—
Other Properties
5.18
Leases
0.30
Goodwill And Other Intangible Assets
7.07
Goodwill
6.69
Other Intangible Assets
0.38
Investments And Advances
—
Other Investments
—
Other Non Current Assets
1.03
Total Liabilities Net Minority Interest
12.01
Current Liabilities
7.85
Payables And Accrued Expenses
3.66
Payables
2.11
Accounts Payable
2.11
Current Accrued Expenses
1.55
Pensionand Other Post Retirement Benefit Plans Current
3.63
Current Debt And Capital Lease Obligation
0.30
Current Capital Lease Obligation
0.30
Other Current Liabilities
0.26
Total Non Current Liabilities Net Minority Interest
4.16
Long Term Debt And Capital Lease Obligation
4.16
Long Term Capital Lease Obligation
4.16
Preferred Securities Outside Stock Equity
—
Stockholders Equity
90.58
Common Stock Equity
90.58
Capital Stock
0.03
Common Stock
0.03
Preferred Stock
0.00
Share Issued
29.27
Ordinary Shares Number
29.27
Treasury Shares Number
0.00
Additional Paid In Capital
253.81
Retained Earnings
-163.26
Gains Losses Not Affecting Retained Earnings
-0.00
Other Equity Adjustments
-0.00
Total Equity Gross Minority Interest
90.58
Total Capitalization
90.58
Working Capital
81.24
Invested Capital
90.58
Total Debt
4.46
Capital Lease Obligations
4.46
Net Tangible Assets
83.51
Tangible Book Value
83.51
Available For Sale Securities
—
Investmentin Financial Assets
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-45.34
+17.55%
-55.00
-12.32%
-48.97
-11.04%
-44.10
Cash Flow From Continuing Operating Activities
-45.34
+17.55%
-55.00
-12.32%
-48.97
-11.04%
-44.10
Net Income From Continuing Operations
-56.02
+8.21%
-61.04
-14.15%
-53.47
-5.86%
-50.51
Depreciation Amortization Depletion
0.35
-8.13%
0.39
+9.37%
0.35
+26.99%
0.28
Depreciation
0.32
-8.79%
0.36
+10.22%
0.32
+30.59%
0.25
Amortization Cash Flow
0.03
+0.00%
0.03
+0.00%
0.03
-2.62%
0.03
Depreciation And Amortization
0.35
-8.13%
0.39
+9.37%
0.35
+26.99%
0.28
Amortization Of Intangibles
0.03
+0.00%
0.03
+0.00%
0.03
-2.62%
0.03
Stock Based Compensation
6.31
-2.93%
6.50
+13.52%
5.73
+40.91%
4.06
Asset Impairment Charge
0.35
+5.09%
0.33
-20.31%
0.41
-20.69%
0.52
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
0.00
-69.15%
0.01
+72.23%
0.00
-23.81%
0.01
Gain Loss On Sale Of PPE
0.00
-69.15%
0.01
+72.23%
0.00
-23.81%
0.01
Change In Working Capital
3.82
+513.23%
-0.93
+5.05%
-0.97
-156.76%
1.72
Change In Receivables
—
0.00
-100.00%
0.01
-94.69%
0.23
Changes In Account Receivables
—
0.00
-100.00%
0.01
-94.69%
0.23
Change In Prepaid Assets
0.49
+2078.03%
-0.02
+85.60%
-0.17
+39.28%
-0.28
Change In Payables And Accrued Expense
2.50
+898.29%
-0.31
+18.69%
-0.38
-117.22%
2.23
Change In Accrued Expense
2.90
+1543.62%
-0.20
-127.82%
0.72
+52.14%
0.47
Change In Payable
-0.40
-257.40%
-0.11
+89.87%
-1.11
-162.88%
1.76
Change In Account Payable
-0.40
-257.40%
-0.11
+89.87%
-1.11
-162.88%
1.76
Change In Other Current Assets
1.11
+526.36%
-0.26
+10.11%
-0.29
+19.28%
-0.36
Change In Other Current Liabilities
-0.28
+13.99%
-0.33
-135.11%
-0.14
-30.18%
-0.11
Investing Cash Flow
-88.74
-435.69%
26.43
+262.30%
7.30
-82.56%
41.83
Cash Flow From Continuing Investing Activities
-88.74
-435.69%
26.43
+262.30%
7.30
-82.56%
41.83
Net PPE Purchase And Sale
-0.14
-67.57%
-0.08
+75.24%
-0.34
+53.84%
-0.74
Purchase Of PPE
-0.14
-67.57%
-0.08
+75.24%
-0.34
+53.84%
-0.74
Capital Expenditure
-0.14
-67.57%
-0.08
+75.24%
-0.34
+53.84%
-0.74
Net Investment Purchase And Sale
-88.60
-434.07%
26.52
+247.15%
7.64
-82.06%
42.57
Purchase Of Investment
-88.60
-1537.58%
-5.41
+87.89%
-44.66
+10.86%
-50.10
Sale Of Investment
0.00
-100.00%
31.93
-38.95%
52.30
-43.57%
92.68
Net Business Purchase And Sale
—
—
—
0.00
Financing Cash Flow
226.58
+4172.32%
5.30
-81.35%
28.44
+149558.35%
0.02
Cash Flow From Continuing Financing Activities
226.58
+4172.32%
5.30
-81.35%
28.44
+149558.35%
0.02
Net Common Stock Issuance
229.52
+5316.51%
4.24
-84.97%
28.20
0.00
Proceeds From Stock Option Exercised
0.79
-28.60%
1.11
+148.88%
0.44
+48.09%
0.30
Net Other Financing Charges
-3.73
-8991.11%
-0.04
+79.88%
-0.20
+27.58%
-0.28
Changes In Cash
92.50
+497.66%
-23.26
-75.81%
-13.23
-487.72%
-2.25
Beginning Cash Position
36.14
-39.16%
59.41
-18.22%
72.64
-3.01%
74.89
End Cash Position
128.65
+255.92%
36.14
-39.16%
59.41
-18.22%
72.64
Free Cash Flow
-45.49
+17.42%
-55.08
-11.71%
-49.31
-9.96%
-44.84
Amortization Of Securities
-0.16
+39.91%
-0.26
+74.53%
-1.02
-493.75%
-0.17
Common Stock Issuance
229.52
+5316.51%
4.24
-84.97%
28.20
0.00
Issuance Of Capital Stock
229.52
+5316.51%
4.24
-84.97%
28.20
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category